Sotera Health (NASDAQ:SHC) Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC trimmed its position in shares of Sotera Health (NASDAQ:SHC - Free Report) by 80.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,970 shares of the company's stock after selling 50,487 shares during the period. Squarepoint Ops LLC's holdings in Sotera Health were worth $164,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of SHC. BNP Paribas Financial Markets purchased a new stake in shares of Sotera Health during the fourth quarter valued at approximately $208,000. Ananym Capital Management LP bought a new stake in Sotera Health during the 4th quarter valued at $13,680,000. Bank of Montreal Can boosted its position in Sotera Health by 10.6% during the 4th quarter. Bank of Montreal Can now owns 18,184 shares of the company's stock valued at $249,000 after buying an additional 1,740 shares during the period. Envestnet Portfolio Solutions Inc. grew its holdings in Sotera Health by 17.3% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 15,839 shares of the company's stock worth $217,000 after acquiring an additional 2,340 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Sotera Health by 45.1% in the 4th quarter. Bank of New York Mellon Corp now owns 1,630,736 shares of the company's stock worth $22,308,000 after acquiring an additional 507,147 shares during the last quarter. 91.03% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on SHC shares. Barclays cut their price target on shares of Sotera Health from $16.00 to $12.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Piper Sandler reduced their price target on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Wall Street Zen downgraded shares of Sotera Health from a "buy" rating to a "hold" rating in a research note on Saturday, June 7th. Finally, The Goldman Sachs Group upgraded Sotera Health from a "neutral" rating to a "buy" rating and lifted their price target for the company from $14.00 to $17.00 in a research report on Monday, May 5th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $15.80.

Sotera Health Price Performance

NASDAQ:SHC traded down $0.31 during trading hours on Thursday, reaching $11.75. The stock had a trading volume of 1,190,427 shares, compared to its average volume of 1,218,947. Sotera Health has a 52 week low of $9.53 and a 52 week high of $17.08. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The company has a 50 day moving average price of $11.82 and a two-hundred day moving average price of $12.54. The stock has a market capitalization of $3.34 billion, a PE ratio of 47.00 and a beta of 1.87.

Sotera Health (NASDAQ:SHC - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. The company had revenue of $254.52 million during the quarter, compared to the consensus estimate of $245.56 million. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. Sotera Health's revenue was up 2.6% on a year-over-year basis. During the same period last year, the company earned $0.13 earnings per share. As a group, sell-side analysts anticipate that Sotera Health will post 0.61 earnings per share for the current fiscal year.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.